Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PLX
PLX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PLX News
Protalix BioTherapeutics Reports FY 2025 Results with Mixed Performance
Mar 19 2026
NASDAQ.COM
Protalix BioTherapeutics Q4 2025 Earnings Call Insights
Mar 18 2026
seekingalpha
Protalix BioTherapeutics Reports Disappointing Earnings
Mar 18 2026
seekingalpha
Protalix BioTherapeutics Earnings Announcement Scheduled
Mar 17 2026
seekingalpha
Protalix BioTherapeutics Schedules Financial Results Conference Call
Mar 11 2026
Newsfilter
Elfabrio's New Dosing Regimen Approved by EU
Mar 09 2026
Globenewswire
Elfabrio's New Dosing Regimen Approved by EU
Mar 09 2026
Newsfilter
Ellomay Capital Shareholders Sell Stakes and Board Restructuring
Mar 04 2026
Newsfilter
Protalix's New Dosing Regimen Recommended for Approval
Jan 30 2026
stocktwits
EMA Endorses New Dosing Regimen for Elfabrio
Jan 30 2026
seekingalpha
CHMP Endorses New Treatment Regimen for Fabry Disease
Jan 30 2026
Globenewswire
Elfabrio's New Dosing Regimen Receives Positive Opinion from CHMP
Jan 30 2026
Globenewswire
Elfabrio's New Dosing Regimen Receives Positive Opinion from CHMP
Jan 30 2026
Newsfilter
Pluxee Reports Q1 2026 Revenues Up 9% to €308 Million
Jan 07 2026
Globenewswire
Protalix Advances PRX-115 for Uncontrolled Gout Amid Rising Global Prevalence
Jan 05 2026
PRnewswire
Protalix and Secarna Collaborate on ASO Therapies for Rare Kidney Disorders
Dec 17 2025
NASDAQ.COM
Show More News
